A prognostic signature of six necroptosis-related miRNAs for predicting the overall survival of breast cancer patients

Breast cancer (BRCA) is the most frequent malignant disease and cause of death in females. Recent studies have uncovered the crucial roles of necroptosis-related miRNAs in diverse cancers, including BRCA. However, the significance of necroptosis-related miRNA in predicting the prognosis of BRCA remains largely undefined. This study aimed at constructing a miRNA risk signature related to necroptosis and a nomogram for estimating the prognosis of BRCA. The miRNA expression data and related clinical information were downloaded from the BRCA cohort (containing tissue samples from BRCA patients and normal para-cancer patients) of The Cancer Genome Atlas (TCGA) database. We analyzed the miRNA expression profile and screened the differentially expressed necroptosis-related miRNAs between BRCA and non-tumor samples. Then, a risk signature for BRCA patients was developed based on prognostic necroptosis-related miRNAs. The prognostic value of the risk signature was determined by Cox regression analysis. We also constructed a prognostic nomogram based on risk signature and clinicopathological characteristics, and evaluated its clinical potential using a calibration chart. Lastly, to identify potential therapeutic target for BRCA. Six necroptosis-related miRNAs (miR-141-3p, miR-148a-3p, miR-200a-5p, miR-223-3p, miR-425-5p, miR-7-5p) were differentially expressed between normal and BRCA tissues, including five up-regulated miRNAs and one down-regulated miRNA. They were used to construct the risk signature. Receiver Operating Characteristic (ROC) curve analysis indicated that the risk signature had good sensitivity and specificity (2-year area under curve (AUC): 0.627; 3-year AUC: 0.647) and was an independent prognostic factor (univariate Cox regression: hazard ratio (HR) = 1.8066, 95% confidence interval (CI) (1.2867–2.5365), p < 0.05; multivariate Cox regression: HR = 1.5246, 95% CI (1.0830–2.1462), p < 0.05). Calibration chart showed that the nomogram had good accuracy for predicting the prognosis of BRCA patients. We also identified miR-223a-3p as a potential therapeutic target for BRCA. This study identified 6 promising necroptosis-related miRNAs, which were used to construct a signature model to predict BRCA patients’ prognosis. Further, a nomogram based on risk signatures and clinicopathological characteristics was constructed and showed promising potential as an effective and individualized diagnostic tool.

Breast cancer; Necroptosis; Risk signature; Prognostic prediction; Survival

[1] Nagini S. Breast cancer: current molecular therapeutic targets and new players. Anti-Cancer Agents in Medicinal Chemistry. 2017; 17: 152–163.

[2] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. A Cancer Journal for Clinicians. 2021; 71: 209–249.

[3] Anderson WF, Katki HA, Rosenberg PS. Incidence of breast cancer in the United States: current and future trends. Journal of the National Cancer Institute. 2011; 103: 1397–1402.

[4] Anderson WF, Rosenberg PS, Petito L, Katki HA, Ejlertsen B, Ewertz M, et al. Divergent estrogen receptor-positive and -negative breast cancer trends and etiologic heterogeneity in Denmark. International Journal of Cancer. 2013; 133: 2201–2206.

[5] Mullooly M, Murphy J, Gierach GL, Walsh PM, Deady S, Barron TI, et al. Divergent oestrogen receptor-specific breast cancer trends in Ireland (2004–2013): amassing data from independent western populations provide etiologic clues. European Journal of Cancer. 2017; 86: 326–333.

[6] Joko-Fru WY, Miranda-Filho A, Soerjomataram I, Egue M, Akele-Akpo MT, N’da G, et al. Breast cancer survival in sub-Saharan Africa by age, stage at diagnosis and human development index: a population-based registry study. International Journal of Cancer. 2020; 146: 1208–1218.

[7] Nagini S. Breast cancer: current molecular therapeutic targets and new players. Anti-Cancer Agents in Medicinal Chemistry. 2017; 17: 152–163.

[8] Christofferson DE, Yuan J. Necroptosis as an alternative form of programmed cell death. Current Opinion in Cell Biology. 2010; 22: 263–268.

[9] Nikoletopoulou V, Markaki M, Palikaras K, Tavernarakis N. Crosstalk between apoptosis, necrosis and autophagy. Biochimica et Biophysica Acta. 2013; 1833: 3448–3459.

[10] Sun L, Wang H, Wang Z, He S, Chen S, Liao D, et al. Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell. 2012; 148: 213–227.

[11] Tanzer M, Tripaydonis A, Webb A, Young S, Varghese L, Hall C, et al. Necroptosis signalling is tuned by phosphorylation of MLKL residues outside the pseudokinase domain activation loop. The Biochemical Journal. 2015; 471: 255–265.

[12] Liu Y, Chen Q, Zhu Y, Wang T, Ye L, Han L, et al. Non-coding RNAs in necroptosis, pyroptosis and ferroptosis in cancer metastasis. Cell Death Discovery. 2021; 7: 210.

[13] Höckendorf U, Yabal M, Herold T, Munkhbaatar E, Rott S, Jilg S, et al. RIPK3 restricts myeloid leukemogenesis by promoting cell death and differentiation of leukemia initiating cells. Cancer Cell. 2016; 30: 75–91.

[14] Shahsavari Z, Karami-Tehrani F, Salami S, Ghasemzadeh M. RIP1K and RIP3K provoked by shikonin induce cell cycle arrest in the triple negative breast cancer cell line, MDA-MB-468: necroptosis as a desperate programmed suicide pathway. Tumor Biology. 2016; 37: 4479–4491.

[15] Novohradsky V, Markova L, Kostrhunova H, Trávníček Z, Brabec V, Kasparkova J. An anticancer Os (II) bathophenanthroline complex as a human breast cancer stem cell-selective, mammosphere potent agent that kills cells by necroptosis. Scientific Reports. 2019; 9: 13327.

[16] Shen F, Pan X, Li M, Chen Y, Jiang Y, He J. Pharmacological inhibition of necroptosis promotes human breast cancer cell proliferation and metastasis. OncoTargets and Therapy. 2020; 13: 3165–3176.

[17] Hill M, Tran N. MiRNA interplay: mechanisms and consequences in cancer. Disease Models & Mechanisms. 2021; 14: 1–9.

[18] Liu B, Li J, Cairns MJ. Identifying miRNAs, targets and functions. Briefings in Bioinformatics. 2014; 15: 1–19.

[19] MacFarlane L, R. Murphy P. MicroRNA: biogenesis, function and role in cancer. Current Genomics. 2010; 11: 537–561.

[20] Hata A, Kashima R. Dysregulation of microRNA biogenesis machinery in cancer. Critical Reviews in Biochemistry and Molecular Biology. 2016; 51: 121–134.

[21] Yang Y, Qu A, Wu Q, Zhang X, Wang L, Li C, et al. Prognostic value of a hypoxia-related microRNA signature in patients with colorectal cancer. Aging. 2020; 12: 35–52.

[22] Lin S, Gregory RI. MicroRNA biogenesis pathways in cancer. Nature Reviews Cancer. 2015; 15: 321–333.

[23] Xu J, Wu KJ, Jia QJ, Ding XF. Roles of miRNA and lncRNA in triple-negative breast cancer. Journal of Zhejiang University-Science B. 2020;21: 673–689.

[24] Tang X, Hou Y, Yang G, Wang X, Tang S, Du Y, et al. Stromal miR-200s contribute to breast cancer cell invasion through CAF activation and ECM remodeling. Cell Death and Differentiation. 2016; 23: 132–145.

[25] Kong X, Li G, Yuan Y, He Y, Wu X, Zhang W, et al. MicroRNA-7 inhibits epithelial-to-mesenchymal transition and metastasis of breast cancer cells via targeting FAK expression. PLoS One. 2012; 7: e41523.

[26] Qian X, Xiao F, Chen Y, Yuan J, Liu X, Wang L, et al. Computerized assessment of the tumor-stromal ratio and proposal of a novel nomogram for predicting survival in invasive breast cancer. Journal of Cancer. 2021; 12: 3427–3438.

[27] Cao M, Cai J, Yuan Y, Shi Y, Wu H, Liu Q, et al. A four-gene signature-derived risk score for glioblastoma: prospects for prognostic and response predictive analyses. Cancer Biology & Medicine. 2019;16: 595–605.

[28] Zhao X, Cui L. A robust six-miRNA prognostic signature for head and neck squamous cell carcinoma. Journal of Cellular Physiology. 2020; 235: 8799–8811.

[29] Kamarudin AN, Cox T, Kolamunnage-Dona R. Time-dependent ROC curve analysis in medical research: current methods and applications. BMC Medical Research Methodology. 2017; 17: 53.

[30] Namdar K, Haider MA, Khalvati F. A modified AUC for training convolutional neural networks: taking confidence into account. Frontiers in Artificial Intelligence. 2021; 4: 582928.

[31] Yang Z, Lu S, Wang Y, Tang H, Wang B, Sun X, et al. A novel defined necroptosis-related miRNAs signature for predicting the prognosis of colon cancer. International Journal of General Medicine. 2022; 15: 555–565.

[32] Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z, et al. ClusterProfiler 4.0: a universal enrichment tool for interpreting omics data. Innovation. 2021; 2: 100141.

[33] Jiang M, Li C, Pan C, Lv W, Ren Y, Cui X, et al. Nomogram for predicting transmural bowel infarction in patients with acute superior mesenteric venous thrombosis. World Journal of Gastroenterology. 2020; 26: 3800–3813.

[34] Balachandran VP, Gonen M, Smith JJ, DeMatteo RP. Nomograms in oncology: more than meets the eye. The Lancet Oncology. 2015; 16: e173–e180.

[35] Wu J, Zhang H, Li L, Hu M, Chen L, Xu B, et al. A nomogram for predicting overall survival in patients with low-grade endometrial stromal sarcoma: a population-based analysis. Cancer Communications. 2020; 40: 301–312.

[36] Zheng W, Li K, Zhu W, Ding Y, Wu Q, Tang Q, et al. Nomogram prediction of overall survival based on log odds of positive lymph nodes for patients with penile squamous cell carcinoma. Cancer Medicine. 2020; 9: 5425–5435.

[37] Zhang W, Fang M, Dong D, Wang X, Ke X, Zhang L, et al. Development and validation of a CT-based radiomic nomogram for preoperative prediction of early recurrence in advanced gastric cancer. Radiotherapy and Oncology. 2020; 145: 13–20.

[38] Wang W, Yang Z, Ouyang Q. A nomogram to predict skip metastasis in papillary thyroid cancer. World Journal of Surgical Oncology. 2020; 18: 167.

[39] Yang S, Liu G. Targeting the Ras/Raf/MEK/ERK pathway in hepatocel-lular carcinoma. Oncology Letters. 2017; 13: 1041–1047.

[40] Pandian J, Panneerpandian P, Devanandan HJ, Sekar BT, Balakrishnan K, Selvarasu K, et al. Identification of the targeted therapeutic potential of doxycycline for a subset of gastric cancer patients. Annals of the New York Academy of Sciences. 2020; 1467: 94–111.

[41] Provenzano PP, Inman DR, Eliceiri KW, Keely PJ. Matrix density-induced mechanoregulation of breast cell phenotype, signaling and gene expression through a FAK-ERK linkage. Oncogene. 2009; 28: 4326–4343.

[42] Hung S, Chen W, Lee Y, Su J, Juan Y, Lin I, et al. Rhopaloic acid A induces apoptosis, autophagy and MAPK activation through ROS-mediated signaling in bladder cancer. Phytomedicine. 2021; 92: 153720.

[43] Barzaman K, Karami J, Zarei Z, Hosseinzadeh A, Kazemi MH, Moradi-Kalbolandi S, et al. Breast cancer: biology, biomarkers, and treatments. International Immunopharmacology. 2020; 84: 106535.